NCT06537674View on ClinicalTrials.gov

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

HER2+ Breast Cancer

Interventions

DRUG

Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection

Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection

All Listed Sponsors

lead

Jiangsu Famous Medical Technology Co., Ltd.

INDUSTRY

NCT06537674 - Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer | Biotech Hunter | Biotech Hunter